Aldolase a in pan-cancer and lung squamous cell carcinoma: prognostic value and macrophage-driven immune suppression unveiled by multi-omics and cohort validation
Our findings establish ALDOA as a robust prognostic biomarker and a key regulator of macrophage-mediated immune suppression in LUSC. Its involvement in tumor metabolism, immune evasion, and therapy resistance suggests that targeting ALDOA could enhance both metabolic inhibition strategies and immune checkpoint blockade therapies. Future research should focus on mechanistic studies and therapeutic interventions targeting ALDOA to improve treatment outcomes in LUSC.
Authors
- Xiaopei Shen (ORCID: https://orcid.org/0000-0002-0004-4228)
- Yujing Du (ORCID: https://orcid.org/0000-0001-8123-3815)
- Xiumei Hu (ORCID: https://orcid.org/0000-0003-2760-734X)
- Fanjie Meng (ORCID: https://orcid.org/0000-0002-2167-021X)
- Wei Wang (ORCID: https://orcid.org/0000-0002-7698-2499)
- Bin Hu (ORCID: https://orcid.org/0000-0001-5906-1527)
- Xincheng Li (ORCID: https://orcid.org/0000-0001-5159-7036)
- Ying Ji (ORCID: https://orcid.org/0000-0002-2252-429X)
Institutions
- Capital Medical University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1186/s12935-025-04043-y
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Capital Medical University
- Beijing Nova Program